Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Prognostic significance of PD-L1 and PD-L2 in breast cancer

Texto completo
Autor(es):
Baptista, Mauricio Z. [1] ; Sarian, Luis Otavio [1] ; Derchain, Sophie F. M. [1] ; Pinto, Glauce A. [2] ; Vassal, Jose [2]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] State Univ Campinas UNICAMP, Fac Med Sci, Womens Hosp CAISM, Dept Obstet & Gynecol, BR-13083970 Campinas, SP - Brazil
[2] State Univ Campinas UNICAMP, Fac Med Sci, Womens Hosp CAISM, Lab Investigat & Mol Pathol LAPE, BR-13083970 Campinas, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: HUMAN PATHOLOGY; v. 47, n. 1, p. 78-84, JAN 2016.
Citações Web of Science: 82
Resumo

PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognostic value is still to be defined. In this study, we investigate the correlation between PD-L1 and PD-L2 protein expressions with clinical and pathologic features and disease-free survival and overall survival. To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, stages I, II, and III, with detailed clinical and outcome data. PD-L1 expression was present in 56.6% (107/189), and PD-L2 expression was identified in 50.8% (97/191) of breast cancer cases. Younger age at diagnosis, lymph node positivity, negative estrogen receptor, and recurrence at distant sites were all associated with both PD-L1 and PD-L2 expressions. The presence of larger tumors was associated only with PD-L1 expression. In our study, PD-L1 expression was significantly associated with better overall survival (P = .04) in breast cancer patients. Despite its association with poor clinical and pathologic features, PD-L1 expression emerges as a positive prognostic biomarker in breast cancer. This survival result might be due to the presence of a strong antitumor immune response leading to PD-L1 expression. (C) 2015 Elsevier Inc. All rights reserved. (AU)

Processo FAPESP: 13/25683-3 - Comparação do perfil genômico de mulheres brasileiras e norte-americanas portadoras de câncer de mama receptor de estrógeno positivo/HER2 negativo
Beneficiário:Luís Otávio Zanatta Sarian
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 08/02469-8 - Instabilidade genômica em neoplasias malignas da mama em função da presença do receptor de estrógeno e da concentração de alumínio intracelular
Beneficiário:Luís Otávio Zanatta Sarian
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 12/15059-8 - Avaliação de biomarcadores para detecção de neoplasia maligna em mulheres com tumor anexial
Beneficiário:Sophie Françoise Mauricette Derchain
Linha de fomento: Auxílio à Pesquisa - Regular